Clinical Trials Logo

Filter by:
NCT ID: NCT00168792 Terminated - Clinical trials for Myocardial Infarction

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

Start date: November 2003
Phase: Phase 4
Study type: Interventional

To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

NCT ID: NCT00168766 Completed - Clinical trials for Relapsing-remitting Multiple Sclerosis

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Start date: January 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.

NCT ID: NCT00166244 Completed - Clinical trials for De Novo Renal Transplant Recipient.

Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation

Start date: May 2003
Phase: Phase 4
Study type: Interventional

Determine the value of a clinically feasible strategy of therapeutic drug monitoring compared with fixed dosing in de novo MMF treated renal transplant recipients with respect to the incidence of treatment failure.

NCT ID: NCT00163527 Completed - Asthma Clinical Trials

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Start date: April 2003
Phase: Phase 3
Study type: Interventional

Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma. The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.

NCT ID: NCT00163007 Completed - Stroke Clinical Trials

Nutritional Therapy for Stroke Patients

Start date: May 2005
Phase: Phase 2/Phase 3
Study type: Interventional

Prospective, short-term studies in patients admitted for acute stroke have shown an increased risk of infections, bedsores, impaired functional outcome, slower rate of recovery, poorer rehabilitation potential and higher mortality in patients with a poor nutritional status. In hospitals without routine nutritional assessment and individual nutrition management plans, the risk of patients developing malnutrition may be increased. In this study, patients admitted for acute stroke are randomised into either receiving nutritional therapy derived from estimated individual nutritional intake and nutritional needs, or nutritional therapy based on routine care without routine assessment of nutritional status, intake, or needs. The primary outcome measure is the percentage of patients with weight loss ≥ 5 % at three month follow-up.

NCT ID: NCT00162123 Completed - Melanoma Clinical Trials

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.

NCT ID: NCT00161655 Completed - Psoriasis Clinical Trials

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Start date: April 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

NCT ID: NCT00161616 Completed - Tibial Fractures Clinical Trials

Study Evaluating InductOs in Diaphyseal Tibia Fractures

Start date: September 2003
Phase: Phase 4
Study type: Interventional

Demonstrate a larger proportion of subjects with healed fractures among subjects treated with InductOs and reamed, locked intramedullary nailing compared to subjects treated with reamed, locked intramedullary nailing alone.

NCT ID: NCT00161005 Unknown status - Clinical trials for Acute Myocardial Infarction

Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction

Start date: February 2005
Phase: N/A
Study type: Interventional

In the district areas of Norway patients with acute myocardial infarction with ST-elevation, are treated with thrombolysis. An increasing part of them receives thrombolysis before arrival to the local hospital.Usually these patients have been sent to an invasive center if thrombolysis fails or the patient gets ischemic symptoms during the stay. This study will compare this strategy against immediate transportation to an invasive center after the patient has received thrombolysis.

NCT ID: NCT00160706 Completed - Crohn's Disease Clinical Trials

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

PRECiSE 4
Start date: February 2004
Phase: Phase 3
Study type: Interventional

A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] due to an exacerbation of Crohn's Disease.